1940P CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)?

C. Linossi,I.G. Funingana, M. Petruzzelli,B.H. Rala de Paula,M. O'Donovan, M. Andrea,S. Hewitt, A.L. Williams,N. Grehan, A. Redmond,E.C. Smyth,R.D. Baird, E.M. Godfrey,M. Di Pietro, I. Faull, S. Dovedi,R.C. Fitzgerald,S. Pacey

Annals of Oncology(2020)

引用 0|浏览31
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要